To interfere and to anti-interfere: The interplay between hepatitis C virus and interferon

Viral Immunology

Volumn 15, Issue 1, 2002, Pages 95-119

  He, Yupeng ^a   Katze, Michael G ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; INTERFERON; NONSTRUCTURAL PROTEIN 5A; PROTEIN E2; PROTEIN KINASE; RNA ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; DNA MICROARRAY; HEPATITIS C VIRUS; IMMUNE RESPONSE; MOLECULAR MODEL; PERSISTENT VIRUS INFECTION; REVIEW; SIGNAL TRANSDUCTION; VIRION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS RESISTANCE;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0036211313     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/088282402317340260     Document Type: Review

References (242)

1. Fas antigen expression on hepatocytes predicts the short- and long-term response to interferon therapy in patients with chronic hepatitis C
2. Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins
3. Epidemiology of hepatitis C
4. Hepatitis G virus infection in the United States
5. Permanent response to alpha- interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum
6. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy
7. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A
8. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha
9. Novel cell culture systems for the hepatitis C virus
10. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy
11. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561
12. Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection
13. Reversal of the interferonsensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene
14. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C
15. Mutations in the E2PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment
16. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha
17. Interferons alpha and beta as immune regulators - A new look
18. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections
19. Efficient initiation of HCV RNA replication in cell culture
20. A perspective on the clinical effectiveness and tolerance of interferon-alpha
21. The coming impact of gene expression profiling on the diagnosis and treatment of HCV-associated liver disease
22. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
23. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa
24. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase
25. Viral inhibition of interferon signal transduction
26. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy
27. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
28. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation
29. Nonstructural protein 5A of hepatitis C virus inhibits the function of karyopherin beta3
30. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system
31. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
32. PKR - A protein kinase regulated by double-stranded RNA
33. The double-stranded RNA-dependent protein kinase PKR: Structure and function
34. Regulation of the interferon-inducible eIF-2 alpha protein kinase by small RNAs
35. The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferonalpha
36. The scientific challenge of hepatitis C
37. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling
38. Duration of HCV infection as a predictor of nonresponse to interferon
39. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway
40. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins
41. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
42. Factors predictive of a beneficial response to therapy of hepatitis C
43. Molecular virology of the hepatitis C virus
44. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers
45. Hepatitis C and hepatocellular carcinoma
46. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity
47. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region
48. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
49. Hepatitis C virus quasispecies populations during chronic hepatitis C infection
50. Analyzing the mechanisms of interferon-induced apoptosis using CrmA and hepatitis C virus NS5A
51. Clinical significance of hepatitis C virus genotypes and quasispecies
52. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
53. Side effects of interferon-alpha in treating hepatitis C virus infection
54. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and doublestranded RNA
55. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis
56. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway
57. Therapy of hepatitis C
58. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C
59. Expression of interferon-alpha receptor mRNA in the liver chronic liver diseases associated with hepatitis C virus: Relation to effectiveness of interferon therapy
60. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver
61. Mutations in the interferon-sensitivity determining region of hepatitis C virus and transcriptional activity of the nonstructural region 5A protein
62. Molecular clones of hepatitis C virus: Applications to animal models
63. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
64. Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase
65. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase
66. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance
67. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
68. Sendai virus C proteins must interact directly with cellular components to interfere with interferon action
69. Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis
70. Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon
71. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha
72. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C
73. Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death
74. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP
75. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth
76. Gene expression profile of Huh7 cells stably expressing NS5A demonstrates an up-regulation of IL-8, contributing to IFN-resistance in these cells
77. The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin
78. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons
79. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C
80. Interferons: Cell signaling, immune modulation, antiviral response and virus countermeasures
81. How does interferon exert its cell growth inhibitory effect?
82. T-lymphocyte subpopulations as factors predicting clinical response to interferon in hepatitis C virus-related chronic active hepatitis
83. Effect of alpha interferon on the hepatitis C virus replicon
84. Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy
85. Serum levels of soluble interleukin-2 receptors and effects of interferon-alpha for patients with chronic hepatitis C virus
86. Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C
87. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase lalpha to dephosphorylate the alpha subunit of the eukaryotic translation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase
88. Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A
89. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway
90. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same
91. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus
92. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon
93. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
94. Hepatitis C: The clinical spectrum of disease
95. Management of hepatitis C: Current and future perspectives
96. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection
97. Response to retreatment with interferon-alpha plus ribavirin in chronic hepatitis C patients is independent of the NS5A gene nucleotide sequence
98. Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A
99. STATs and MAPKs: Obligate or opportunistic partners in signaling
100. Activation of p38 mitogen-activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded RNA and encephalomyocarditis virus: Involvement of RNase L, protein kinase R, and alternative pathways
101. Relationship between the intrahepatic expression of interferonalpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases
102. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)
103. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection
104. Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype
105. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients
106. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator
107. Regulation of the interferon-induced PKR: Can viruses cope?
108. The war against the interferon-induced dsRNA-activated protein kinase: Can viruses win?
109. Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A
110. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha
111. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients
112. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment
113. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection
114. Sendai virus blocks alpha interferon signaling to signal transducers and activators of transcription
115. Evading the interferon response: Hepatitis C virus and the interferon-induced protein kinase
116. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: Role of IRF-1 and NF-kappaB
117. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy
118. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis
119. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C
120. Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C
121. Regulation of STAT-dependent pathways by growth factors and cytokines
122. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C
123. Costs of hepatitis C
124. Effects of adenovirus E1A protein on interferon-signaling
125. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion
126. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha
127. Mutations in hepatitis C virus RNAs conferring cell culture adaptation
128. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
129. Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: Correlation with disease activity and response to interferon-alpha
130. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies
131. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: Relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma
132. Binding of the influenza virus NS1 protein to doublestranded RNA inhibits the activation of the protein kinase that phosphorylates the e1F-2 translation initiation factor
133. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a
134. The molecular virology of hepatitis C
135. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner
136. Current and future treatment of hepatitis C
137. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection
138. Evolution of hypervariable region 1 of hepatitis C virus in primary infection
139. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype la/I chronic hepatitis C liver biopsies correlates with response to IFN therapy
140. Hepatitis C virus replication in mice with chimeric human livers
141. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway
142. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer
143. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients
144. Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection
145. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection
146. Effect of interferon treatment on serum 2′,5′-oligoadenylate synthetase levels in hepatitis C-infected patients
147. HCV NS5A 2209-2248 amino acid substitutions affect serum 2,5AS activities
148. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?
149. Apoptosis and pathogenesis of viral hepatitis C-An update
150. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
151. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
152. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment
153. Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: Relationship to the therapeutic response
154. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
155. Hepatitis C and iron
156. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
157. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response
158. Hepatitis C virus (HCV) NS5A protein: Role in HCV replication and resistance to interferon-alpha
159. Hepatitis C virus resistance to antiviral therapy
160. The non-structural 5A protein of hepatitis C virus
161. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations
162. Effect of alpha interferon (IFN-alpha) on 2′-5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: Relationship to the antiviral effect of IFN-alpha
163. Persistent replication of a selectable Hepatitis C virus full length genome in cell culture
164. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs
165. Evidence for a deficiency of interferon response in mononuclear cells from hepatitis C viremic patients
166. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner
167. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response
168. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy
169. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection
170. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1infected patients treated with interferon
171. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication
172. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
173. Treatment of chronic hepatitis C by interferon for longer duration than six months
174. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma
175. PKR: A new name and new roles
176. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C
177. Racial differences in responses to therapy with interferon in chronic hepatitis C
178. Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321
179. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: Properties of the NS5A-associated kinase
180. The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element
181. Commentary: Iron metabolism in hepatitis C infection
182. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: Role of complex formation and the E3 N-terminal domain
183. Alpha interferon treatment of chronic hepatitis C
184. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus
185. The PKR protein kinase-An interferon-inducible regulator of cell growth and differentiation
186. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type la are associated with treatment response
187. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
188. Quasispecies heterogeneity of the carboxy-terminal part of the e2 gene including the pephd and sensitivity of hepatitis c virus 1b isolates to antiviral therapy
189. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response
190. Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease(s) in mammalian cells
191. Mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: An end to the controversy
192. Chronic hepatitis C: The viral load per liver cell before treatment as a new marker to predict long-term response to IFN-alpha therapy
193. Natural history of hepatitis C
194. Interferon-induced antiviral actions and their regulation
195. Current and future therapies of hepatitis C
196. Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons
197. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy
198. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection
199. Clinical relevance of hepatitis C virus genotypes
200. Variability of hepatitis C virus
201. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon
202. Nuclear localization and intramolecular cleavage of N-terminally deleted NS5A protein of hepatitis C virus
203. Poxvirus-encoded soluble cytokine receptors
204. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa
205. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection
206. How cells respond to interferons
207. The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: A new face of death?
208. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling
209. The amino terminal deletion mutants of hepatitis C virus nonstructural protein NS5A function as transcriptional activators in yeast
210. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A
211. Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus
212. Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus
213. Hepatitis C virus and interferon resistance: It's more than just PKR
214. Hepatitis C virus: Evasion of the interferon-induced antiviral response
215. Hepatitis C virus and interferon resistance
216. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
217. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain
218. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C
219. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C
220. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
221. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection
222. Effects of iron overload on the immune system
223. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection
224. The polyoma virus T antigen interferes with interferon-inducible gene expression
225. Maximal activation of transcription by Statl and Stat3 requires both tyrosine and serine phosphorylation
226. PKR: A sentinel kinase for cellular stress
227. Serpentine receptors and STAT activation: More than one way to twin a STAT
228. Intracellular signalling: Putting JAKs on the kinase MAP
229. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response
230. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase
231. Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: Relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C
232. Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells
233. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus
234. Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection
235. Paramyxoviridae use distinct virus-specific mechanisms to circumvent the interferon response
236. Serum hepatitis C virus RNA levels in chronic hepatitis C-Importance for outcome of interferon alfa-2b treatment
237. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa
238. Requirement of serine phosphorylation for formation of STAT-promoter complexes
239. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription